COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 591: Articles 5901-5910  | Next

Utilization of Cycle Threshold Values of RTPCR SARS-Cov-2 Among Admitted Patients in a Public Hospital
Laurito, A. A., Arengo, A. M. C.
10.1101/2022.12.05.22283130 — Posted: 2022-12-06
Impact of COVID-19 Vaccinations in India - A Statewise Analysis
Adhikary, A., Pal, M., Maiti, R., Ghosh, P.
10.1101/2022.12.02.22283013 — Posted: 2022-12-06
Involvement of fatigue in the effect of transcranial magnetic stimulation (TMS) on depression following COVID-19 and COVID-19 vaccination: a before-after study
Kamamuta, A., Takagi, Y., Takahashi, M., Kurihara, K., Shibata, H., Tanaka, K., Hata, K.
10.1101/2022.12.02.22282982 — Posted: 2022-12-05
Perceptions, readiness and recommendations of traditional herbalists to integrate traditional and modern medicine in controlling COVID-19 epidemics in Northeast Ethiopia: An interpretive qualitative study
Kassaw, M. W., Mohammed, M. H., Mohammed, O. A.
10.1101/2022.12.01.22282963 — Posted: 2022-12-05
Discovering Social Determinants of Health from Case Reports using Natural Language Processing: Algorithmic Development and Validation
Raza, S.
10.1101/2022.11.30.22282946 — Posted: 2022-12-05
Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: a cohort study using OpenSAFELY-TPP
Lemanska, A., Andrews, C. D., Fisher, L., Bacon, S., Mehrkar, A., Inglesby, P., Davy, S., Patalay, P., Goldacre, B., MacKenna, B., The OpenSAFELY Collaborative, , Walker, A. J.
10.1101/2022.12.02.22283026 — Posted: 2022-12-05
Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: new tricks for old dogs
Shekunov, E. V., Zlodeeva, P. Z., Efimova, S. S., Muryleva, A. A., Zarubaev, V. V., Slita, A. V., Ostroumova, O. S.
10.1101/2022.12.05.519140 — Posted: 2022-12-05
High resolution cryo-EM structures of two potently SARS-CoV-2 neutralizing monoclonal antibodies of same donor origin that vary in neutralizing Omicron variants
Rencilin, C. F., Ansari, M. Y., Chatterjee, A., Deshpande, S., Mukherjee, S., Singh, R., Jayatheertha, S., Reddy, P. M., Das, P., Hingankar, N., Rathore, D., Varadarajan, R., Bhattacharya, J., Dutta, S.
10.1101/2022.12.03.518949 — Posted: 2022-12-05
DiffDomain enables identification of structurally reorganized topologically associating domains
Hua, D., Gu, M., Zhang, X., Du, Y., Xie, H., Qi, L., Du, X., Bai, Z., Zhu, X., Tian, D.
10.1101/2022.12.05.519135 — Posted: 2022-12-05
Covidscope: An atlas-scale COVID-19 resource for single-cell meta analysis at sample and cell levels
Yin, D., Cao, Y., Chen, J., Mak, C. L. Y., Yu, K. H. O., Lin, Y., Ho, J. W. K., Yang, J. Y. H.
10.1101/2022.12.03.518997 — Posted: 2022-12-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).